番茄社区app

In trial, datopotamab deruxtecan increased progression-free survival by 2 months

25 drugs chosen so far comprise about a third of Medicare Part D spending on prescription drugs

Mortality hazard reduced by one third at 7 years versus trastuzumab

Greater burden of disease in younger folks and women, American Cancer Society projects

New report emphasizes greater public awareness, education

"We should not look at variant allele frequency to make a decision," said Virginia Kaklamani, MD

Hormone receptor-positive patients with high TMB may fare well with immunotherapy

Lack of biomarkers handicaps decision making in era of expanding treatment options

No improvement in survival or impact on recurrence, but pending studies leave door ajar

Study was stopped early due to enrollment issues, but lessons can still be learned

Significant improvement in 5-year distant relapse-free interval with higher risk score

Radiotherapy also resulted in fewer treatment-related adverse events

Nearly identical 5-year outcomes with no surgery, sentinel lymph node biopsy

Study results are "historic," expert says